Effect of Palbociclib Plus Letrozole on Patient-Reported Health-Related Quality of Life: Extended Follow-Up of the PALOMA-2 Trial

    March 2025 in “ ESMO Open ”
    Nadia Harbeck, Véronique Dièras, Karen A. Gelmon … Hope S. Rugo
    Studysummary In this extended follow-up of the PALOMA-2 trial, no significant differences in overall quality of life were observed between first-line treatments for metastatic breast cancer, but palbociclib plus letrozole showed some benefits regarding side-effects and hair loss.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on esmoopen.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. A Systematic Review of Health-Related Quality of Life Outcomes in Patients With Advanced Breast Cancer Treated With Palbociclib Journal of Comparative Effectiveness Research · 2024
    2. CDK4/6 Plus Aromatase Inhibitor-Induced Alopecia in Breast Cancer Patients Journal of Clinical Oncology · 2019
    3. Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis Expert Review of Anticancer Therapy · 2017